Who are Vfend (voriconazole) tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Voriconazole high dose, fast itraconazole tablet, Voriconazole low dose, Voriconazole clinical practice, medium itraconazole tablet, Diflucan (fluconazole).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vfend-voriconazole-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vfend (voriconazole) tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vfend (voriconazole) tablet (Vfend (voriconazole) tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal. Area: Infectious Disease.

marketed Triazole antifungal Cytochrome P450 14α-demethylase (CYP51) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vfend (voriconazole) tablet (Vfend (voriconazole) tablet) — Seoul National University Hospital. Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vfend (voriconazole) tablet TARGET	Vfend (voriconazole) tablet	Seoul National University Hospital	marketed	Triazole antifungal	Cytochrome P450 14α-demethylase (CYP51)
Voriconazole high dose	Voriconazole high dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
Voriconazole low dose	Voriconazole low dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
medium itraconazole tablet	medium itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal CYP51 (lanosterol 14α-demethylase)
Diflucan (fluconazole)	Diflucan (fluconazole)	Pfizer	marketed	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal class)

University of Maryland, Baltimore · 3 drugs in this class
Manjunath Prakash Pai · 2 drugs in this class
Pfizer · 2 drugs in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
University of California, San Francisco · 1 drug in this class
University of Minnesota · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vfend (voriconazole) tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/vfend-voriconazole-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab